ライフサイエンスコーパス: low dose

1 ti-CD22 ADCs (CD22 0 Jurkat, all inactive at low doses).

2 rferes with acupuncture analgesia, even at a low dose.

3 rism agent that is highly infectious at very low doses.

4 1 triple negative breast cancer in mice at a low dose (1.7 micromol kg(-1), 1 T), but not in oestroge

5 ree of the treatment group subjects received low-dose (1 x 10(10) vector genomes) and 3 high-dose (1

6 with AHF who were previously receiving no or low-dose (12.5 mg or 25 mg daily) spironolactone and had

7 ezepelumab at a dose of 70 mg every 4 weeks (low dose; 145 patients), 210 mg every 4 weeks (medium do

8 afety and effectiveness of a next-generation low-dose (2-microg/mm(2) surface dose of paclitaxel) DCB

9 tly inhibited SK1 and VEGF expression, while low dose (5 nM) docetaxel had no significant effect.

10 signed to receive either placebo or a single low dose (50 mg) of the D2/D3 receptor antagonist amisul

11 Three of the patients received a low dose (6.7x10(13) vg per kilogram of body weight), an

12 n either group was immunized with adjuvanted low-dose A(H5N1) subvirion vaccine.

13 Infection with low-dose A/X31 H3N2 led to prolonged deterioration of lu

14 Increasing evidence suggest that low-dose alcohol consumption (LAC) reduces the incidence

15 t compared high doses of ACEI or ARB against low doses among patients with HF with reduced ejection f

16 ere are specific aspects of the use of these low doses and low plasma concentrations that require spe

17 at in BALB/c mice R21 is immunogenic at very low doses and when administered with the adjuvants Abisc

18 A total of 6 studies (4841 patients in low-dose and 4330 patients in high-dose groups) were inc

19 secretion of inflammatory cytokines at very low doses, and suppressing function at high doses.

20 Here we show that a combination therapy of low-dose anti-CD3 with a clinical-grade self-containing

21 evaluated cost-effectiveness of ticagrelor + low-dose ASA in patients with prior MI within the prior

22 long-term treatment with ticagrelor 60 mg + low-dose ASA yields a cost-effectiveness ratio suggestin

23 to ASA alone, ticagrelor 60 mg twice daily + low-dose ASA, or ticagrelor 90 mg twice daily + low-dose

24 -dose ASA, or ticagrelor 90 mg twice daily + low-dose ASA.

25 atelet therapy (3613 of 4527 [80%]) received low-dose aspirin (50 to 150 mg/d); 914 (20%) received hi

26 A growing body of research suggests daily low-dose aspirin (ASA) reduces heart diseases and colore

27 3 years earlier, treatment with ticagrelor + low-dose aspirin (ASA) reduces the risk of cardiovascula

28 Current use of low-dose aspirin (cases: 26.7%, controls: 22.4%; adjuste

29 ular (CV) death, MI, or stroke compared with low-dose aspirin alone, but at an increased risk of majo

30 used concurrently with an antiplatelet drug (low-dose aspirin and a VKA: 3.6% of cases and 1.1% of co

31 no association between postdiagnosis use of low-dose aspirin and cancer-specific mortality among pat

32 It is uncertain whether the intake of low-dose aspirin during pregnancy reduces the risk of pr

33 Low-dose aspirin for cancer prevention is often cited as

34 performed a cohort study of 601 527 users of low-dose aspirin for primary or secondary prevention in

35 In long-term users, discontinuation of low-dose aspirin in the absence of major surgery or blee

36 Treatment with low-dose aspirin in women at high risk for preterm preec

37 Low-dose aspirin prescriptions were identified from link

38 study is to evaluate the impact of DHA with low-dose aspirin therapy on periodontal bacterial profil

39 Adherence to low-dose aspirin treatment in the absence of major surge

40 e independent cohorts in the United Kingdom, low-dose aspirin usage was not associated with increased

41 rvals (CIs) for cancer-specific mortality by low-dose aspirin use after adjusting for potential confo

42 Use of low-dose aspirin, clopidogrel, a vitamin K antagonist (V

43 s meta-analysis including patients on mainly low-dose aspirin, NOACs were found to be more effective

44 under the curve [AUC] 24 968) compared with low-dose (AUC-38 225) or standard-dose NCEM (AUC-38 685)

45 afety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients.

46 nduced neoplasia from early-life exposure to low-dose bisphenol A (BPA).

47 or in healthy HIV-1-infected persons, single low-dose BMS-936559 infusions appeared to enhance HIV-1-

48 ogressed to carcinoma in rats given neonatal low-dose BPA with adult T+E but not in rats given adult

49 compared with those treated with vehicle or low-dose BRD3308.

50 ON: In mild recent-onset asthma, once daily, low-dose budesonide decreases SARE risk, reduces lung fu

51 age) undergoing HCT for marrow failure using low-dose busulfan-containing regimen survived.

52 -), IL-4(-/-), and IL-4Ralpha(-/-) mice with low-dose C. trachomatis inoculums.

53 In addition, we found that a low dose Cae (5 ug/kg) could induce pancreatic injury in

54 apitulated by the systemic administration of low-dose carboxyatractyloside, a specific inhibitor of A

55 DISCUSSION AND The theoretical merits of the low-dose carcinogenesis hypothesis are well founded with

56 Low-dose CDKi outperforms high-dose CDKi in controlling

57 In a repetitive, low-dose challenge study, we observe robust protection a

58 The low-dose chemotherapy conditioning regimen depleted bloo

59 single dose of CAR-19 T cells 2 days after a low-dose chemotherapy conditioning regimen of cyclophosp

60 Conclusion CAR-19 T cells preceded by low-dose chemotherapy induced remission of advanced-stag

61 clinical trial of CAR-19 T cells preceded by low-dose chemotherapy.

62 nt of extinguished preference in response to low-dose cocaine administration did not differ between g

63 In the low-dose cohort, mean endogenous FIX activity increased

64 Moderate-strength evidence suggests that low-dose colchicine is as effective as high-dose colchic

65 dation 2: ACP recommends that clinicians use low-dose colchicine when using colchicine to treat acute

66 We aimed to assess whether ultra-low-dose combination therapy could meet these needs.

67 ch as exhaled breath condensate analysis and low dose computed tomography (CT) as an alternative to c

68 ing cessation counseling in conjunction with low-dose computed tomography (LDCT) lung cancer screenin

69 yclic voltammetry in male rats, we show that low-dose, continuous amphetamine treatment, during self-

70 This double-blind and placebo (or low-dose)-controlled randomized clinical trial was condu

71 ase 2 trial, we assigned patients to receive low-dose crizanlizumab (2.5 mg per kilogram of body weig

72 ast-enhanced CT (CECT) and PET combined with low-dose CT (PET/CT) at baseline, after 2 cycles of chem

73 inarily analyse the usefulness of Whole-Body Low-Dose CT (WBLDCT) in the evaluation of patients with

74 Lung cancer screening with low-dose CT can save lives.

75 ically delineate the anatomic volumes on the low-dose CT component.

76 terogeneity features in both the PET and the low-dose CT components of PET/CT.

77 The repeatability of PET and low-dose CT features should be carefully considered when

78 d to ensure the successful implementation of low-dose CT lung cancer screening in Europe.

79 munity to adopt before the implementation of low-dose CT lung cancer screening.

80 proach should be used for future lung cancer low-dose CT programmes; that individuals who enter scree

81 Therefore, low-dose CT protocols could be a solution.

82 y-specific recovery coefficient based on the low-dose CT scan, method 3 was an enlarged volume of int

83 The standard low-dose CT scans were processed with the iMAR algorithm

84 reatment; and planning for implementation of low-dose CT screening should start throughout Europe as

85 shape and heterogeneity features in PET and low-dose CT varied greatly among metrics.

86 ion with a recovery coefficient based on the low-dose CT.

87 After treatment with low dose CTLA4-Ig, PI3Kgamma (-/-) , but not PI3Kappadel

88 ht after receiving a conditioning regimen of low-dose cyclophosphamide and fludarabine.

89 could be increased using MVA-5T4, metronomic low-dose cyclophosphamide, or a combination of both trea

90 Furthermore, low-dose DAC preserved HSPC-NK killing, proliferation, a

91 Superiority with a low-dose DCB for femoropopliteal interventions was demon

92 ts were randomized (3:1) to treatment with a low-dose DCB or an uncoated percutaneous transluminal an

93 We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this grou

94 Low doses decreased plasma membrane Ca(2+) currents afte

95 Pembrolizumab, pomalidomide, and low-dose dexamethasone have acceptable safety and durabl

96 The presented review of low-dose diagnostic images of a wide spectrum of congeni

97 , we demonstrate that acetaminophen, even at low-dose, disrupts the integrity of TJ and cell-matrix a

98 treatments of mice with MN-anti-miR-10b and low-dose doxorubicin resulted in complete regression of

99 Low dose E2 administered for the first 3-months after BC

100 Taken as a whole, the results suggest that low-dose E2 replacement might be a potentially promising

101 Low-dose effects include persistent delays in mammary gl

102 In situ X-ray scattering, cryo-, and low-dose electron microscopy were used to capture the tr

103 riment designed to investigate the effect of low-dose environmental chemical exposure on normal mamma

104 ntinued, this seems to be minimized by using low doses (especially atropine 0.01%).

105 nd dynamic CT perfusion measurement into one low-dose examination.

106 eciation, rendering the extrapolation to the low dose exposure chemically inconsistent.

107 At low dose exposure, the life span of affected organisms i

108 We delineate the effects upon physiological low-dose exposure to ubiquitous endocrine disrupting che

109 Could ongoing low-dose exposures to a mixture of commonly encountered

110 Once daily, low-dose ferrous sulfate should be considered for childr

111 he supporting principle is that use of these low doses for a limited time in well-controlled, small p

112 nal dysfunction resulting from chronic ultra-low dose GBH exposure.

113 Repeated low-dose grass pollen intradermal allergen injection sup

114 s: BSJYD high dose group, middle dose group, low dose group, captopril group, and control group.

115 one (an acute allergic skin reaction in the low-dose group) was assessed to be causally related.

116 [18%] in the placebo group, 17 [30%] in the low-dose group, and 20 [34%] in the high-dose group).

117 (33%) to the placebo group, 57 (33%) to the low-dose group, and 58 (34%) to the high-dose group.

118 ient in the placebo group, three (5%) in the low-dose group, and two (3%) in the high-dose group; onl

119 Although some grant the absence of low-dose harm, they nevertheless advocate the "prudence"

120 Compared with low dose, high-dose ACEI or ARBs decreased all-cause mor

121 e contrasted MTD strategies as compared with low-dose, high-density metronomic strategies (LDM) for t

122 In vitro, low-dose HMAs did not impair viability of HSPC-NK cells.

123 The use of low-dose HMAs is safe and effective in patients with low

124 ry secondary analysis of the PREMILOC (Early Low-Dose Hydrocortisone to Improve Survival without Bron

125 Early low-dose hydrocortisone treatment has been reported to i

126 al trial of extremely preterm infants, early low-dose hydrocortisone was not associated with a statis

127 D127(+) CD25(high) cells are unresponsive to low-dose IL-2 and in patients have marked proliferative

128 otriene C4 (LTC4), given in combination with low-dose IL-33 to naive wild-type mice, led to synergist

129 y visualized by using the recently developed low-dose imaging technique of transmission electron micr

130 Low-dose immunoglobulin treatment for 6 weeks was not ef

131 produced an inverted-U dose-response, where low doses improved performance but higher doses, similar

132 rst full D1 agonist, dihydrexidine, which at low doses improved working memory in monkeys.

133 nd to have robust P2X7 receptor occupancy at low doses in rat with ED50 values of 0.06 and 0.07 mg/kg

134 f mRNA results in high protein expression at low doses in vitro (<600 pM) and in vivo (1 mg kg(-1) ).

135 Attempts to induce high-avidity T cells by low-dose in vivo vaccination failed because this strateg

136 Low-dose inhaled corticosteroids (ICS) are highly effect

137 Low-dose inocula were associated with short-term, low-ti

138 Chronic low dose inorganic arsenic (iAs) exposure leads to chang

139 Here we demonstrate that a single low-dose intradermal immunization with lipid-nanoparticl

140 icantly protected animals against a repeated low-dose intrarectal challenge with pathogenic SIVmac251

141 ey resulted in enhanced protection against a low-dose intravaginal challenge with a heterologous stra

142 ed with enhanced protection against repeated low-dose, intravaginal challenges with heterologous SIVs

143 Two small trials suggest that low-dose intravenous immunoglobulin (IVIg) may improve t

144 High-dose intravenous NAC administered with low-dose intravenous nitroglycerin is associated with re

145 Low-dose iodine-125 plaque brachytherapy (67.5-81 Gy at

146 e (CHD) are exposed to increasing amounts of low-dose ionizing radiation (LDIR) from cardiac procedur

147 ortant for studying biological effects under low-dose ionizing radiation, safety control in medical r

148 Ralpha prevented the induction of priming by low-dose IP3 in females.

149 Specifically, after low-dose IR, keratin 5(+) basal hair bulb progenitors, r

150 formation, is transiently elevated following low dose irradiation and regulates transcription of its

151 VIN, when used at a low dose, is able to preserve wine composition without l

152 e with select antiepileptic drugs (AEDs), in low doses, is usually well tolerated and efficacious.

153 To confirm the efficacy of low-dose IVIg compared with placebo in reducing pain dur

154 ks of 15 to receive placebo (normal saline), low-dose ketamine (0.5 mg/kg), or high dose ketamine (1.

155 Two rapid-acting antidepressant strategies, low-dose ketamine (KT) and sleep deprivation (SD) therap

156 results do not support the use of adjunctive low-dose ketamine in routine ECT treatment.

157 ent; we tested this in a randomised trial of low-dose ketamine.

158 Eyes were divided into apex low-dose (LD) and high-dose (HD) groups (</= or > median

159 , brain) and were consistently larger at the low dose level.

160 e hemodynamic support after cardiac surgery, low-dose levosimendan in addition to standard care did n

161 impact the modeled force of infection; iii) low-dose linear, concave functions allow the basic repro

162 considered when selecting a functional form: low-dose linearity, scalability, concavity, and whether

163 Injection of these mice with low-dose LPS resulted in elevated serum TNF levels compa

164 Credible evidence of imaging-related low-dose (<100 mGy) carcinogenic risk is nonexistent; it

165 wing promise for efficient spectrum imaging, low-dose mapping of beam-sensitive specimens, trace elem

166 015 evaluated the scientific support for the low-dose mixture hypothesis of carcinogenesis and develo

167 Low-Dose Mixture Hypothesis of Carcinogenesis Workshop:

168 In this study, we explore the effect of low dose N-acetyl-L-cysteine therapy, delivered using a

169 t alanine aminotransferase elevations in the low-dose (n = 1) and higher-dose (n = 2) cohorts were tr

170 The success of these cases suggests low-dose naltrexone as a novel therapy for Hailey-Hailey

171 rify the mechanism and to define the role of low-dose naltrexone for treatment of Hailey-Hailey disea

172 Each patient was treated with low-dose naltrexone hydrochloride at a dosage of 1.5 to

173 To assess low-dose naltrexone hydrochloride in the treatment of re

174 The possible mechanism may involve low-dose naltrexone influencing opioid or toll-like rece

175 To determine whether low-dose naltrexone is an effective treatment for Hailey

176 Low-dose naltrexone may represent a low-cost and low-ris

177 Discontinuation of low-dose naltrexone resulted in flaring of symptoms, whi

178 th severe Hailey-Hailey disease treated with low-dose naltrexone who achieved clinical resolution of

179 Low-dose naltrexone, 3 mg nightly, titrated to 4.5 mg ni

180 te the safety, efficacy, and tolerability of low-dose naltrexone, in conjunction with single-day bupr

181 eared within 2 to 3 days on rechallenge with low-dose naltrexone.

182 - 5% and 37.8 +/- 3%, P < .05) compared with low-dose NCEM (12WU/g).

183 -dose NAC (29 g over 2 days) with background low-dose nitroglycerin (7.2 mg over 2 days) on early car

184 Under conditions of low-dose NTBC, FAH(-/-) pigs developed liver fibrosis an

185 fortified in juice or food, at a relatively low dose of 15 mug/d, was effective in increasing serum

186 t of appropriate antipsychotic medication, a low dose of amphetamine enhances brain processes associa

187 2-depleted (SOD2(+/)(-)) mice in response to low dose of angiotensin II (0.3 mg/kg per day) compared

188 IDs to date, it appears that a comparatively low dose of celecoxib administered to low-risk subjects

189 Intratumoral delivery of HMGN1 with low dose of Cytoxan cured mice bearing small (slashed ci

190 Preconditioning with a low dose of endotoxin confers unparalleled protection ag

191 Most important, OPG-Fc combined with a low dose of formoterol, a member of a new generation of

192 ally exposing human primary fibroblasts to a low dose of hydrogen peroxide.

193 ertilized one-cell stage eggs, followed by a low dose of irradiation, frequently results in random in

194 Coadministration of caffeine with a low dose of l-DOPA reduces dyskinesia in animals with st

195 2%) mice previously infected with a relative low dose of L. monocytogenes CD44(hi)CD4(+) T cells from

196 as inhibition of actin polymerization with a low dose of latrunculin A disrupts the targeting of micr

197 t neutrophils do not directly respond to the low dose of LPS used in the study (2 ng/kg body weight).

198 te monotherapies) and single gametocytocidal low dose of primaquine, vector control and surveillance.

199 d a high number of functional islets using a low dose of recombinant collagenase enzyme mixture (RCEM

200 The concept involves the use of very low doses of a radionuclide-labeled compound for imaging

201 ion studies uncovered surprising benefits of low doses of ABBV-075 coupled with bortezomib and azacit

202 These data indicate that very low doses of Adenovirus-vectored consensus vaccines indu

203 r-mediated mechanism even in the presence of low doses of albumin.

204 or-mediated mechanism even after exposure to low doses of albumin.

205 roperties would be similarly effective, (ii) low doses of antibiotics can be as effective as high dos

206 the early 1950s, amid initial findings that low doses of antibiotics served as growth promoters in a

207 er humic acid (SRHA) at pH 5.1 +/- 0.2 using low doses of chlorine (0.1 to 0.50 mg free Cl2/L), with

208 and conditioned place preference induced by low doses of cocaine.

209 Finally, we review evidence suggesting that low doses of DA agonists that effectively treat TS decre

210 ology that are not sufficiently prevented by low doses of exercise.

211 Immunization with low doses of gp96 primes T helper type 1 (Th1) immune re

212 suggest non-targeted effects (NTE) occur for low doses of high linear energy transfer (LET) radiation

213 h concentrations or prolonged treatment with low doses of HU can cause cell lethality.

214 t activated CD8 T cells become responsive to low doses of IL-2 more quickly than CD4 T cells, and pro

215 CD4 nor naive CD8 T cells are responsive to low doses of IL-2.

216 ine stem cells (GSCs) to survive exposure to low doses of ionizing radiation (IR) as a model of adult

217 chloride channel modified to be activated by low doses of ivermectin (but not glutamate) is highly ef

218 utcomes is unclear; although, treatment with low doses of levothyroxine, which is usually used to tre

219 experimental findings have demonstrated that low doses of low energy helium ions can be used to tailo

220 lso enhanced fusion but was less potent, and low doses of methanol mildly inhibited fusion.

221 the pro-tumoural role of MG, we showed that low doses of MG induced AGEs formation and tumour growth

222 ion, with enhanced neuronal firing following low doses of mGluR2/3 agonists.

223 Our data suggest that low doses of mGluR2/3 stimulation may have therapeutic e

224 fferentiated to higher frequencies of TCM at low doses of MP Rapa MPs.

225 Feeding high but not low doses of peanut before sensitization induced toleran

226 High or low doses of peanut extract were administered to pups ev

227 ased photoreceptor survival at both high and low doses of PERK inhibitor.

228 The role of very low doses of radiation (LDR) in the context of EMT has n

229 y, we showed that combination treatment with low doses of rapamycin and carbamazepine was able to att

230 taining the potential biological activity of low doses of resveratrol has not been extensively studie

231 pproved collagen sponges are used to deliver low doses of small molecule glycogen synthase kinase (GS

232 raction between FKBP12 and calcineurin, with low doses of the Food and Drug Administration (FDA)-appr

233 to cancer cells upon brief irradiation with low doses of visible light, and potent at sub-micromolar

234 trials have been limited by short duration, low doses of vitamin D, variability in participants' vit

235 A low-dose of MAGL inhibitors produces antidepressant effe

236 ng epithelial cells chronically exposed to a low-dose of single-walled carbon nanotubes (SWCNTs).

237 Increasingly, low-dose once-a-week cisplatin is substituted because of

238 sequentially into one of three dose cohorts (low dose [one participant], intermediate dose [one parti

239 Antibiotic administration to mice before low dose oral inoculation increases L. monocytogenes gro

240 Two low-cost interventions-low-dose oral misoprostol tablets and transcervical Fole

241 Here, we administered low-dose oral rapamycin to a knock-in (KI) mouse model o

242 Importantly, low-dose oral rapamycin was sufficient to extend Tk2KI/K

243 These findings do not support low-dose oxygen in this setting.

244 s with acute stroke, the prophylactic use of low-dose oxygen supplementation did not reduce death or

245 To assess whether routine prophylactic low-dose oxygen therapy was more effective than control

246 01), and 6% (-11 to 23) for high-dose versus low-dose (p=0.32).

247 cebo group (difference, 0.12 liters with the low dose [P=0.01], 0.11 liters with the medium dose [P=0

248 Low dose PAV (10 microg/ml) +/- CHC and unmodified algin

249 Colon cancer cells treated with low-dose PEITC for >1 month exhibited stable alterations

250 of 15-PGDH inhibitors to initiate or amplify low-dose PGE2-mediated cervical ripening or (ii) EP2 rec

251 Single low-dose primaquine (PQ) reduces Plasmodium falciparum i

252 re information is needed about the safety of low-dose primaquine in populations where G6PD deficiency

253 Ketamine in low doses produces both rapid and sustained antidepressa

254 Low-dose r-tPA alone did not dissolve emboli, but was sy

255 n inactivation alone, or in combination with low-dose r-tPA, did not lead to fibrinogen degradation,

256 nt Ph+ leukemia cells to investigate whether low dose radiation (LDR) in combination with TKI therapy

257 On the contrary, low-dose radiation does not cause, but more likely helps

258 isk may better inform safe levels of chronic low-dose radiation exposure.

259 e need for dose optimization in imaging: the low-dose radiation of medical imaging has no documented

260 arly important for chemical exposures in the low-dose range that may be affecting crucial cancer hall

261 nt, our results support the possibility that low-dose rapamycin, while not targeting the underlying m

262 ncer who require or choose active treatment, low-dose rate brachytherapy (LDR) alone, EBRT alone, and

263 that islet function can be improved by using low-dose rC1rC2 (RCEM).

264 assay demonstrated better islet function for low-dose RCEM (area under the curve [AUC] 24 968) compar

265 Additionally, low-dose RCEM islets retained better morphology (confirm

266 Low-dose RCEM was efficient in digesting entire pancreas

267 dle- and high-dose data do not constrain the low-dose response, and different dose-response forms tha

268 ay antithrombotic therapy approach combining low-dose rivaroxaban (in place of aspirin) with a P2Y12

269 INTERPRETATION: Low-dose rivaroxaban taken twice a day plus aspirin once

270 ay antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the trea

271 s receiving involved-sites radiotherapy with low dose schemas.

272 4]) patients on placebo, 22 (39% [27-52]) on low-dose SCIg, and 19 (33% [22-46]) on high-dose SCIg ha

273 ir addition to a DNMTi, thus devising a new, low-dose, sequential regimen that imparts a robust anti-

274 All participants underwent low-dose single-section quantitative CT of the L4 verteb

275 10-<20 mg, simvastatin 40-<80 mg), and 12.9% low-dose statins (atorvastatin <20 mg, rosuvastatin <10

276 tion of a hormetic effect of MG defined by a low-dose stimulation and a high-dose inhibition of tumou

277 In response to multiple low-dose streptozotocin (STZ), hep-tg animals developed

278 MSCs were adoptively transferred to multiple low-dose streptozotocin (STZ)-induced T1DM.

279 er pancreatic insulin content after multiple low-dose streptozotocin treatment.

280 cles were injected in right eyes of 14 rats (low dose; study group I, high dose; study group II).

281 tacrolimus variability in a "Symphony" style low-dose tacrolimus based regime, by collecting data fro

282 Two patients were weaned to a low-dose tacrolimus monotherapy together with monthly be

283 rall, combination fludarabine-melphalan with low-dose TBI after haplocord stem cell transplant assure

284 essential portion of the field of view and a low-dose technique to image the remainder of the body.

285 The efficacy of low-dose ticagrelor is consistent over time with a trend

286 immune checkpoint blockade, chemotherapy, or low-dose TNF, complete tumor regression and long-lasting

287 Aortic EC were stimulated with low-dose TNFalpha (0.3 ng/ml) in a microfluidic channel

288 regions of atherosusceptible-SS inflamed by low-dose TNFalpha.

289 nary evidence indicates that the addition of low-dose total body irradiation (TBI) (2-4 Gy) to reduce

290 offer a preclinical proof of concept for the low-dose use of isoform-specific PI3Kdelta/gamma inhibit

291 Here, we report that the combined low-dose use of two anti-inflammatory drugs, aspirin and

292 tinction memory after extinction training by low-dose USP methylene blue (MB).

293 as cationic adjuvant formulation 09, render low-dose vaccination a feasible and promising approach f

294 ells of higher functional avidity induced by low-dose vaccinations showed higher cytokine release per

295 Low-dose vaginal estrogen, lidocaine, and dehydroepiandr

296 e risk reductions were 25% (95% CI 6-41) for low-dose versus placebo (p=0.007), 30% (12-46) for high-

297 d has the potential to be used for accurate, low-dose vessel-specific morphologic and physiologic ass

298 Precise detection of low-dose X- and gamma-radiations remains a challenge and

299 ally, we evaluated the anti-cancer effect of low-dose YC-1 (1 mg/kg) + G (2 g/kg) and I (1 unit/3 g G

300 a HIF-1alpha inhibitor, and we revealed that low-dose YC-1 (10 microM) suppressed HIF-1alpha expressi